Sakura Bio is an innovative biotech company aiming to transform the future of cell therapy with effective, durable, and accessible T and NK cell treatments.

Our core technology, T-Boost, enhances the potency, persistence, and resistance of reprogrammed T and NK cells against the tumor microenvironment, addressing critical limitations of current CAR-T and other cell therapies.

T-Boost is a modular, plug-in solution that integrates easily into existing workflows and supports a wide range of modalities, including CAR-T, TCR-T, CAR-NK, TILs, and next-gen approaches for both solid and hematologic tumors.

Backed by strong preclinical data, T-Boost offers a scalable, platform-level opportunity to improve therapeutic outcomes and address major pain points in a fast-growing market.